The Ryan Haight Act and Telehealth Ketamine: History, Exemptions, and Ongoing Debate

The Ryan Haight Act and Telehealth Ketamine

The Ryan Haight Act is the federal law that determines whether a doctor can prescribe a controlled substance, including ketamine, after only a video visit. Passed in 2008, it generally requires an in-person medical evaluation before a controlled substance prescription, a rule that stood in direct conflict with the at-home telehealth ketamine model until the COVID-19 pandemic prompted the Drug Enforcement Administration (DEA) to temporarily waive it. Understanding the Ryan Haight Act and telehealth ketamine together explains why current at-home ketamine treatment runs on temporary federal flexibilities rather than a permanent rule, and what could change if those flexibilities end.

The Story Behind the Law

Ryan Haight was an 18-year-old from La Mesa, California, who died in 2001 from an overdose of Vicodin obtained through an online pharmacy. He had received the prescription over the internet from a physician who never evaluated him in person. His death became a catalyst for federal legislation targeting the prescribing of controlled substances through online pharmacies without proper medical oversight.

Congress passed the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (Public Law 110-425) with bipartisan support. Its purpose was to stop the kind of pill mill prescribing that led to Ryan's death, not to regulate an internet-based telemedicine industry that barely existed at the time. But the provisions it created became the central legal obstacle for telehealth ketamine more than a decade later.

Core Provisions of the Act

The Act's most consequential provision requires that a practitioner who prescribes a controlled substance based on an internet consultation must have first conducted at least one in-person medical evaluation of that patient, at a location where both the practitioner and the patient are physically present.

The law defines "prescribing by means of the internet" broadly enough to cover any prescription issued after an online questionnaire or video conversation that does not include an in-person exam, which captures nearly all telehealth prescribing of controlled substances.

The Act also directed the DEA to create a "special registration" category that would let qualified telemedicine practitioners prescribe controlled substances without an in-person exam under defined safeguards. The DEA did not finalize that special registration process for more than a decade, which left telehealth ketamine providers without a lawful path around the in-person requirement until the COVID-19 exemptions arrived.

The Act carved out a few narrow exceptions to the in-person rule: hospital- or clinic-based telemedicine where a practitioner is physically present at the patient's location, Indian Health Service telemedicine, qualifying state-based telemedicine programs, and specialized settings with in-person clinician oversight. None of these cover a patient at home connecting to a remote physician by video, which is the core telehealth ketamine model.

How the Act Blocked At-Home Ketamine Telehealth

From 2008 until the COVID-19 emergency in 2020, the Ryan Haight Act effectively barred the direct-to-consumer at-home ketamine model. In-person IV ketamine clinics could operate normally, but no provider could evaluate a patient by video alone and send a ketamine prescription home without first conducting an in-person exam. Some clinics tried workarounds, such as requiring one initial in-person visit before starting a telehealth relationship, but this significantly limited the convenience and access telehealth is meant to provide.

The COVID-19 Turning Point

The March 2020 public health emergency declaration changed the legal landscape overnight. The DEA invoked its emergency authority to waive the Ryan Haight in-person requirement for the duration of the emergency, allowing practitioners to conduct entire evaluation and prescribing relationships by video, including for controlled substances like ketamine.

The telehealth ketamine industry emerged almost immediately after. Companies launched in 2020 and 2021 on the assumption that the exemptions would eventually become permanent or be replaced with a workable long-term framework. See our guide on how to get a ketamine prescription online for how that care model works today.

The Debate Since the Emergency Ended

Once the public health emergency wound down, the central question became what should replace the temporary exemptions. Telehealth ketamine providers and broader telehealth advocates argue that the COVID-era experience showed appropriate controlled substance prescribing can happen over telehealth with good outcomes, without the diversion harms the Ryan Haight Act was written to prevent. They have pushed for permanent flexibilities that preserve remote access.

The DEA's own 2023 proposed rules were widely seen as far more restrictive than the industry wanted, particularly a 30-day limit on telehealth-only prescriptions and a requirement for an in-person evaluation before continuing treatment beyond that window. The proposal drew one of the largest public comment responses the DEA has ever received for a rulemaking.

The underlying tension is about risk models. The Ryan Haight Act responded to a real problem: inappropriate opioid prescribing without clinical evaluation. The DEA's instinct to preserve some in-person requirement reflects a legitimate concern about controlled substance safety. But telehealth ketamine providers argue that the risk profile of sublingual ketamine at therapeutic doses in a screened patient differs from opioid diversion, and that in-person requirements impose real costs on patients without transportation, in rural areas, or with disabilities, who often have the most to gain from telehealth access. Our guide to state ketamine regulations covers how individual states are handling this tension in the meantime.

Where Things Stand in 2026

Congress has not amended the Ryan Haight Act, and the DEA has not finalized a permanent telemedicine prescribing framework, including the special registration process the original law called for. The COVID-era exemptions remain in effect through a series of temporary extensions, which is the current legal basis for telehealth ketamine prescribing. The debate continues on three fronts: what the DEA's permanent rule will require, whether Congress will legislate a statutory framework for telemedicine controlled substance prescribing, and whether the extensions or an eventual permanent rule face a legal challenge. Our telehealth law updates guide tracks the rulemaking as it develops.